Carvedilol to Metoprolol Dose Equivalency
There is no established fixed dose equivalency between carvedilol and metoprolol, but based on guideline target doses and clinical trial data, carvedilol 25 mg twice daily (50 mg/day) is approximately equivalent to metoprolol succinate 200 mg once daily in terms of clinical efficacy for heart failure, though they differ substantially in their pharmacologic effects.
Guideline-Based Target Doses
The most reliable approach to dose equivalency comes from examining the target doses used in major clinical trials that demonstrated mortality benefit:
For Heart Failure:
- Carvedilol: Target dose 25 mg twice daily (50 mg/day total) 1, 2, 3
- Metoprolol succinate CR/XL: Target dose 200 mg once daily 1, 2, 3
These are the doses proven effective in landmark trials (COPERNICUS, US Carvedilol trials for carvedilol; MERIT-HF for metoprolol) and represent the therapeutic targets clinicians should aim for when titrating beta-blockers in heart failure patients 4.
Important Pharmacologic Differences
The drugs are NOT pharmacologically equivalent despite similar clinical outcomes:
Beta-Blockade Characteristics:
- Metoprolol is beta-1 selective at lower doses but becomes progressively non-selective at higher doses 5
- Carvedilol is non-selective (blocks both beta-1 and beta-2) at all doses, plus has alpha-1 blocking activity 6
Exercise Heart Rate Response:
Research demonstrates that despite similar resting heart rates, metoprolol 96 mg/day produces more complete beta-1 blockade during exercise than carvedilol 33 mg/day 7. At peak exercise, patients on metoprolol achieved heart rates of 117 bpm versus 135 bpm on carvedilol (p=0.02), despite similar norepinephrine release 7.
24-Hour Heart Rate Control:
However, when comparing the COMET trial doses (metoprolol tartrate 50 mg twice daily vs carvedilol 25 mg twice daily), both drugs produced similar 24-hour heart rate suppression patterns 8. This suggests that at these specific doses, the degree of beta-1 blockade over 24 hours is comparable.
Clinical Equivalency Considerations
Key distinction: Carvedilol's additional alpha-1 blockade causes greater blood pressure reduction and peripheral vasodilation compared to metoprolol 9, 10. This means:
- Carvedilol causes greater reduction in blood pressure (both sitting and standing) 9
- At rest, carvedilol may cause reflex tachycardia due to peripheral vasodilation, particularly at higher doses (50-100 mg), which can paradoxically increase resting heart rate 10
- Metoprolol provides more consistent heart rate reduction across all activity levels 7
Practical Dosing Algorithm
When converting between agents:
Starting from carvedilol 25 mg twice daily → Switch to metoprolol succinate 200 mg once daily
For lower doses, use proportional scaling:
- Carvedilol 12.5 mg twice daily ≈ Metoprolol succinate 100 mg daily
- Carvedilol 6.25 mg twice daily ≈ Metoprolol succinate 50 mg daily
- Carvedilol 3.125 mg twice daily ≈ Metoprolol succinate 25 mg daily
Monitor closely after conversion for:
- Blood pressure changes (expect higher BP with metoprolol)
- Heart rate at rest and with activity
- Signs of heart failure decompensation
- Adjust diuretics if needed due to different hemodynamic effects
Critical Caveats
Formulation matters: These equivalencies apply to metoprolol succinate (extended-release), NOT metoprolol tartrate (immediate-release). Metoprolol tartrate requires twice-daily dosing and has different pharmacokinetics 1, 11
Not interchangeable for all indications: While clinical outcomes in heart failure trials were similar, the drugs have different effects on exercise capacity, blood pressure, and arrhythmia burden 12, 13
Individual titration required: Both drugs should be titrated to the maximum tolerated dose based on heart rate, blood pressure, and symptoms—not simply converted at a fixed ratio 1, 14
Renal and metabolic effects differ: Carvedilol may cause more acute kidney injury but has more favorable metabolic effects (lower risk of new-onset diabetes) 15, 16